Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.
about
Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas.Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell LymphomaThe Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment.Progress, prospects, and problems in Epstein-Barr virus vaccine development.Genetic factors affecting EBV copy number in lymphoblastoid cell lines derived from the 1000 Genome Project samples.Prognostic factors in hodgkin lymphomaγ-Herpesvirus load as surrogate marker of early death in HIV-1 lymphoma patients submitted to high dose chemotherapy and autologous peripheral blood stem cell transplantation.Blood and marrow transplant clinical trials network state of the Science Symposium 2014Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma.Prognostic impact of Epstein-Barr virus (EBV)-DNA copy number at diagnosis in chronic lymphocytic leukemia.The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseasesEvaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern eraBalancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone.Decreased Prognostic Value of International Prognostic Score in Chinese Advanced Hodgkin Lymphoma Patients Treated in the Contemporary Era.Pharmacotherapy of Hodgkin lymphoma: standard approaches and future perspectives.Decision-making in the management of adult classical Hodgkin's lymphoma: determining the optimal treatment.Haematological cancers in African children: progress and challenges.Prognostic Biomarkers for Hodgkin Lymphoma.Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma.Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.DNA Superresolution Structure of Reed-Sternberg Cells Differs Between Long-Lasting Remission Versus Relapsing Hodgkin's Lymphoma Patients.Mechanisms underlying the association between obesity and Hodgkin lymphoma.Pathogenesis and FDG-PET/CT findings of Epstein-Barr virus-related lymphoid neoplasms.Pretreatment whole blood Epstein-Barr virus-DNA is a significant prognostic marker in patients with Hodgkin lymphoma.Hodgkin lymphoma, HIV, and Epstein-Barr virus in Malawi: Longitudinal results from the Kamuzu Central Hospital Lymphoma study.Plasma Epstein-Barr virus and Hepatitis B virus in non-Hodgkin lymphomas: Two lymphotropic, potentially oncogenic, latently occurring DNA virusesThe prognostic significance of EBV DNA load and EBER status in diagnostic specimens from diffuse large B-cell lymphoma patients.Epstein-Barr viral loads and serum free light chains levels are potential follow-up markers of HIV-related lymphomas.Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma.Plasma Epstein Barr virus (EBV) DNA as a biomarker for EBV associated Hodgkin lymphoma.Cell-free Epstein-Barr virus-DNA in patients with nasopharyngeal carcinoma: Plasma versus urine.Pediatric Hodgkin lymphoma in a South Indian regional cancer center: its immunomorphology, tumor-associated macrophages, and association with Epstein-Barr virus.FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus status.Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignanciesDisparate survival and risk of secondary non-Hodgkin lymphoma in histologic subtypes of Hodgkin lymphoma: a population-based study.A pilot trial of quantitative Epstein-Barr virus polymerase chain reaction in patients undergoing treatment for their malignancy: potential use of Epstein-Barr virus polymerase chain reaction in multiple cancer types.Isolated bone marrow Hodgkin lymphoma in a human immunodeficiency virus-negative patient: a second case.Hodgkin lymphoma: A review and update on recent progress.Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma.Blood Epstein-Barr virus DNA does not predict outcome in advanced HIV-associated Hodgkin lymphoma.
P2860
Q30275251-67E2B7A7-D52A-44F0-8B43-F96E6119C0B2Q30276132-EE52A2E8-B31C-4436-A5EE-4A83E3BA7DFAQ30278553-56395D71-4985-40C1-A150-16E55E9C432EQ33812640-634BE1A3-5FE6-4DA6-A48A-25510A74B405Q33842180-179D4AEB-5ECD-4A5D-BDC5-8C2C4B139C87Q33920147-03A88CC3-E04E-498D-9182-71748CC7C8B6Q35068371-37482011-0D99-473E-8AB0-2E137D17D85FQ35591760-B8B8D289-0417-4F57-8EE9-0777B92BC05AQ36467468-BF0780E9-D9D5-4EE6-8865-33D836C3C8FCQ36739059-37AEC10A-5773-4E37-91C3-802E6A728992Q36825808-7BEF8993-DEC5-4F5F-B2CC-ED52E12B3EDAQ36939926-7811387E-EE62-4583-97A2-8DD70FEACF70Q37383554-3A5EDF79-CD10-4082-B5B1-DD0973BF5638Q37487600-741C398B-35D1-4A2B-A7A0-24277118E609Q38205880-C69853E2-D1DE-4069-8528-BB207940E8D8Q38337152-823B26BF-9CFE-4BC1-B8A4-21B2889EDA48Q38557451-4FF14FE1-5831-4009-90E4-342DC2F7C032Q38588503-D3C16115-50CD-4C4D-A79C-55D49FA30138Q38754419-6361DA05-AD1C-46D2-AFF1-A946C421E127Q38775871-9D2DE204-636B-40FA-B153-D7017E0A1E5AQ38814150-15659161-EF26-4042-A65A-C7C8446B874CQ38910560-33E28991-0FDC-489E-A819-B8362951E8CEQ39301790-A0FC547A-29A2-48B3-8209-3635E725BDEFQ39992915-15155D28-A39A-4FA3-8458-17CA3BA48B1EQ40485032-95C96242-4842-4CEF-9142-6034B7EBAFCAQ40521594-740A5FD6-DC8F-44C4-9FFC-BF98CC0E2A89Q40733407-E354FC5F-17E6-4963-89D7-3834469BA6E9Q40777733-BE17D4DC-8231-4859-994C-33395181D429Q40956947-57F3B56F-2D52-4069-8AAE-91B7F0FCF26BQ40990232-C468BF67-D418-4CC3-B398-A3172D808640Q41050251-0CC7729D-F52B-489F-8947-AF36C0CE6B2BQ41727799-451FC23C-45E0-4188-AD33-705DA1ACECE4Q42332100-EEA9BACE-9605-49AF-8BF3-5AF1800550DEQ42421291-D28E32A8-2A1B-4E88-AEE0-B42CD291CEA6Q45283058-AE5B0445-F987-4C7E-AD4A-6C7468D92441Q45344942-5990DE9A-FF7E-477C-8F1D-AF5FF50A18E1Q45349534-04B84086-FED5-4507-8D01-F0C59EAE09DDQ47807176-477EC99A-9857-4BFF-86AC-33E30992A6CFQ54212216-AAE682C9-0EFE-4126-AE4A-E4EFBC6B6531Q54256361-E38401F0-936A-44B6-8C1E-1D13635AB2C6
P2860
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Plasma Epstein-Barr virus DNA ...... rican cooperative group trial.
@ast
Plasma Epstein-Barr virus DNA ...... rican cooperative group trial.
@en
type
label
Plasma Epstein-Barr virus DNA ...... rican cooperative group trial.
@ast
Plasma Epstein-Barr virus DNA ...... rican cooperative group trial.
@en
prefLabel
Plasma Epstein-Barr virus DNA ...... rican cooperative group trial.
@ast
Plasma Epstein-Barr virus DNA ...... rican cooperative group trial.
@en
P2093
P2860
P50
P1433
P1476
Plasma Epstein-Barr virus DNA ...... erican cooperative group trial
@en
P2093
Brad S Kahl
Bruce D Cheson
Fangxin Hong
Jennifer A Kanakry
King L Tan
Lan L Gellert
M Victor Lemas
Patrick Stiff
Ranjana Advani
P2860
P304
P356
10.1182/BLOOD-2012-09-454694
P407
P577
2013-02-05T00:00:00Z